Nephrocare Health Services has cancelled its scheduled analyst and institutional investor meetings that were set to take place on June 18 and June 19, 2026. The company attributed the cancellation of the HSBC Singapore Conference to unavoidable exigencies.

The decision was communicated to BSE Limited and National Stock Exchange of India Limited on June 17, 2026. The disclosure is submitted pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The original invitation for the meetings was referenced in a letter bearing reference no. NEPHROPLUS/SE/042 dated May 26, 2026. The company's website, www.nephroplus.com , will host the disclosure details.

Kishore Kathri, Company Secretary & Compliance Officer, signed the disclosure on behalf of Nephrocare Health Services Limited.

Nephrocare Health Services disclosed that its overseas step-down wholly-owned subsidiary, Nephrocare Health Care Services Philippines Inc., has acquired assets of a dialysis center for PhP 32,640,000. The acquisition, executed through an Asset Transfer Agreement (ATA) dated June 09, 2026, involves the purchase of identified assets from Amica Healthcare System Corporation located at Dona Soledad, Don Bosco, Paranaque City, Philippines. This strategic expansion strengthens the company's footprint in the dialysis care segment within the international healthcare market.

Transaction Details

The agreement was entered into between Nephrocare Health Care Services Philippines Inc. (Purchaser) and Amica Healthcare System Corporation (Seller). The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key details of the transaction are outlined below:

Key Disclosures

The filing confirmed that the seller is not related to the promoter or promoter group of the company. Consequently, the transaction does not qualify as a related party transaction and was conducted at arm's length. There are no special rights, such as the right to appoint directors or restrict capital structure changes, attached to the agreement. The acquisition marks a significant step in Nephrocare Health Services' operational growth within the international healthcare market.